Role of p2PSA and its related marker PHI in the diagnosis of prostate cancer

doi:10.3969/j.issn.1673-8640.2019.07.006

Abstract

Abstract:

Objective To investigate the role of prostate-specific antigen isoform 2（p2PSA） and its related marker prostate health index（PHI） in the diagnosis of prostate cancer. Methods Serum p2PSA,total prostate-specific antigen（t-PSA） and free prostate-specific antigen（f-PSA） were determined in 50 patients with prostate cancer and 46 patients without prostate cancer. The f-PSA%,p2PSA% and PHI were calculated. Receiver operating characteristic（ROC） curve was used to evaluate the diagnostic efficiency in the diagnosis of prostate cancer. Prostate cancer patients were classified into moderately differentiated adenocarcinoma group（Gleason score≤7,32 cases） and low/undifferentiated carcinoma group（Gleason score>7,18 cases）. The results were analyzed comparatively. Results Age,t-PSA,f-PSA%,p2PSA,p2PSA% and PHI between prostate cancer group and non-prostate cancer group had statistical significance（P<0.05）,and there was no statistical significance in f-PSA between the 2 groups（P>0.05）. ROC curve analysis showed that the areas under curves（AUC） of PHI,p2PSA%,p2PSA,f-PSA% and t-PSA in the diagnosis of prostate cancer were 0.870,0.837,0.762,0.671 and 0.652,respectively. The diagnostic efficiency of PHI and p2PSA% in prostate cancer was better than that of f-PSA% and t-PSA. The levels of f-PSA,p2PSA,f-PSA% and PHI in low/undifferentiated carcinoma group were higher than those in moderately differentiated adenocarcinoma group（P<0.05）,and there was no statistical significance in p2PSA% and t-PSA between the 2 groups（P>0.05）. Conclusions The diagnostic efficiency of PHI for prostate cancer is better than that of t-PSA and f-PSA%,which can be used as an auxiliary diagnostic method for prostate cancer in clinic.

Key words: Prostate-specific antigen isoform 2, Prostate health index, Prostate hyperplasia, Prostate cancer

CLC Number:

R446.1

HUANG Yi, WANG Wenjuan, XU Jing, SHEN Yunyue, LIU Hua, YANG Cuixia. Role of p2PSA and its related marker PHI in the diagnosis of prostate cancer[J]. Laboratory Medicine, 2019, 34(7): 600-604.

Figures/Tables 8

References 15

[1]	韩苏军,张思维,陈万青,等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志,2013,18(4):330-334.
[2]	韩苏军. 中国前列腺癌发病及死亡现状和流行趋势分析[D]. 北京:北京协和医学院,2015.
[3]	朱耀,唐钵,戴波,等. 前列腺健康指数在中国男性前列腺癌诊断中的应用研究[J]. 中华外科杂志,2017,55(10):734-737.
[4]	NA R,YE D,QI J,et al.Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL:results from a multicenter study in China[J]. Prostate,2017,77(11):1221-1229.
[5]	马兰,张倩,张俊华,等. %p2PSA和phi联合检测在前列腺癌中的诊断价值[J]. 医药前沿,2016,6(20):108-109.
[6]	PEYROMAURE M,FULLA Y,DEBRÉ B,et al.Pro PSA :a "pro cancer" form of PSA?[J]. Med Hypotheses,2005,64(1):92-95.
[7]	MIKOLAJCZYK S D,MARKER K M,MILLAR L S,et al.A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer[J]. Cancer Res,2001,61(18):6958-6963.
[8]	巫志宇,罗杰,吴斌,等. 血清前列腺特异性抗原同源异构体p2PSA的体外稳定性评估[J]. 免疫学杂志,2018,34(4):338-342.
[9]	VUKOVIC I,DJORDJEVIC D,BOJANIC N,et al.Predictive value of [-2]propsa(p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0 ng/mL PSA range[J]. Int Braz J Urol,2017,43(1):48-56.
[10]	TAN L G,TAN Y K,TAI B C,et al.Prospective validation of %p2PSA and the prostate health index,in prostate cancer detection in initial prostate biopsies of Asian men,with total PSA 4-10 ng ml-1[J]. Asian J Androl,2017,19(3):286-290.
[11]	NA R,YE D,LIU F,et al.Performance of serum prostate-specific antigen isoform [-2]proPSA(p2PSA) and the prostate health index(PHI) in a Chinese hospital-based biopsy population[J]. Prostate,2015,74(15):1569-1575.
[12]	WANG W,WANG M,WANG L,et al.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer:a meta-analysis[J]. Sci Rep,2014,4:5012.
[13]	吴义启,刘修恒. 前列腺健康指数对前列腺癌的诊断价值[J]. 中华实验外科杂志,2015,32(5):1190-1192.
[14]	闫存玲,李志艳,何群,等. 血清前列腺特异性抗原同源异构体2在前列腺癌诊断中的应用价值[J]. 中华检验医学杂志,2015,38(12):813-817.
[15]	谭思嘉,许露伟,徐郑,等. PHI/PCA3在前列腺癌早期诊断中的应用价值探讨[J]. 中华医学杂志,2016,96(2):100-103.

组别	例数		年龄（岁）	t-PSA（μg/L）		f-PSA（μg/L）		p2PSA（ ng/L）
前列腺癌组	50		71.68±8.04	17.09（8.83~108.70）		1.83（1.19~9.68）		47.70（20.34~299.20）
非前列腺癌组	46		66.83±7.77	11.44（7.28~22.24）		1.54（1.03~3.24）		17.60（9.93~29.90）
统计值			3.01	806.00		923.50		552.50
P值			<0.01	<0.05		>0.05		<0.000 1
组别		f-PSA%（%）			p2PSA%（%）		PHI
前列腺癌组		9.74（6.67~14.13）			24.04（16.67~36.74）		113.00（62.90~277.10）
非前列腺癌组		12.55（9.20~17.14）			10.24（6.75~17.52）		35.79（25.96~62.01）
统计值		791.00			404.00		323.00
P值		<0.01			<0.000 1		<0.000 1

组别	例数		年龄（岁）	t-PSA（μg/L）		f-PSA（μg/L）		p2PSA（ ng/L）
前列腺癌组	50		71.68±8.04	17.09（8.83~108.70）		1.83（1.19~9.68）		47.70（20.34~299.20）
非前列腺癌组	46		66.83±7.77	11.44（7.28~22.24）		1.54（1.03~3.24）		17.60（9.93~29.90）
统计值			3.01	806.00		923.50		552.50
P值			<0.01	<0.05		>0.05		<0.000 1
组别		f-PSA%（%）			p2PSA%（%）		PHI
前列腺癌组		9.74（6.67~14.13）			24.04（16.67~36.74）		113.00（62.90~277.10）
非前列腺癌组		12.55（9.20~17.14）			10.24（6.75~17.52）		35.79（25.96~62.01）
统计值		791.00			404.00		323.00
P值		<0.01			<0.000 1		<0.000 1

项目	AUC（95% CI）	标准误	P值	最佳临界值	敏感性（%）	特异性（%）	约登指数
t-PSA	0.65（0.54 ~0.76）	0.06	0.010	30.72 μg/L	37.25	91.11	1.28
f-PSA	0.59（0.47 ~0.70）	0.06	0.139	5.05 μg/L	33.33	93.33	1.27
p2PSA	0.76（0.66 ~0.86）	0.05	<0.001	0.11 ng/L	70.59	66.67	1.37
f-PSA%	0.67（0.56 ~0.78）	0.06	0.004	34.24%	58.82	88.89	1.48
p2PSA%	0.84（0.76 ~0.92）	0.04	<0.001	1.32%	86.27	71.11	1.57
PHI	0.87（0.80 ~0.94）	0.04	<0.001	75.03	68.63	95.56	1.64

项目	AUC（95% CI）	标准误	P值	最佳临界值	敏感性（%）	特异性（%）	约登指数
t-PSA	0.65（0.54 ~0.76）	0.06	0.010	30.72 μg/L	37.25	91.11	1.28
f-PSA	0.59（0.47 ~0.70）	0.06	0.139	5.05 μg/L	33.33	93.33	1.27
p2PSA	0.76（0.66 ~0.86）	0.05	<0.001	0.11 ng/L	70.59	66.67	1.37
f-PSA%	0.67（0.56 ~0.78）	0.06	0.004	34.24%	58.82	88.89	1.48
p2PSA%	0.84（0.76 ~0.92）	0.04	<0.001	1.32%	86.27	71.11	1.57
PHI	0.87（0.80 ~0.94）	0.04	<0.001	75.03	68.63	95.56	1.64

项目	同一特异性（%）	临界值	敏感性
t-PSA	83.33	8.875 μg/L	28.57
f-PSA	83.33	0.66 μg/L	35.71
f-PSA%	83.33	9.18%	35.71
p2PSA	83.33	21.44 ng/L	28.57
p2PSA%	83.33	20.46%	42.86
PHI	83.33	54.68	50.00